Ultragenyx Pharmaceutical (RARE) Could Be 41% Undervalued As Voucher Sale And EMA Validation Land

Ultragenyx Pharmaceutical (RARE) is back on investors’ radar after two linked catalysts. The EMA validated its Marketing Authorisation Application for rebisufligene etisparvovec, and the business agreed to sell a Rare Pediatric Disease Priority Review Voucher for US$210 million.

The fresh catalysts around Genglycos and rebisufligene etisparvovec arrive after a tough stretch for Ultragenyx Pharmaceutical. The share price return is down about 54% over the past 90 days and the 1-year total shareholder return has fallen roughly 51%. However, the 30-day share price return of about 8% hints that sentiment toward the stock may be starting to recover as investors reassess both growth potential and risk around its rare disease pipeline.

Scan beyond Ultragenyx Pharmaceutical to see how other rare disease and biotech players are priced by checking our curated list of 28 high quality undervalued stocks.

Ultragenyx Pharmaceutical now pairs a broader rare disease portfolio with fresh non dilutive cash on the balance sheet. After such a sharp share price reset, is that combination being valued fairly today?

Most Popular Narrative: 40.5% Undervalued

Ultragenyx Pharmaceutical last closed at $15.48, while the most followed valuation narrative pegs fair value at $26 per share. That gap sets the stage for a sharp debate about whether a deep loss-making pipeline can justify such a higher figure.

"The Ultragenyx Turnaround Thesis" is trapped in a commercial illusion, mistaking a multi-product portfolio for financial stability while ignoring deep-rooted structural inefficiencies.

Here is why the market is mispricing the friction inside RARE’s operational engine:

1. The Multi-Approval Paradox: Bulls cheer the 4 approved rare-disease drugs. This can be viewed as a red flag, since if a biotech generates over $400M in product revenue and still reports losses of $600M+ annually, the commercial model may be fundamentally inefficient. The SG&A required to hunt for rare disease patients may be offsetting top-line gains.

2. The Stripped Royalty Moat: Crysvita is a notable drug, but its economic value to RARE has been affected by complex co-promotion splits with Kyowa Kirin and past royalty monetization deals to fund the pipeline. As a result, the actual net cash flowing back to TopCo may be a fraction of the reported gross revenue.

3. Restructuring as Capital Preservation: The ongoing pipeline changes and corporate restructuring are sometimes presented as a lean transition toward profitability. An alternative view is that these moves are primarily capital-preservation tactics to fund near-term CMC (manufacturing) setup costs for potential upcoming gene-therapy launches without triggering significant equity dilution.

4. Gene Therapy CapEx Friction: Commercializing DTX401 and UX701 could introduce specialized supply-chain and manufacturing friction that a structurally unprofitable biotech may find difficult to absorb without expanding its debt profile.

Ultragenyx’s science is often regarded as strong, but some observers view its commercial execution as a cash-intensive effort with limited room for error at current valuation multiples. Under that view, the safety margin for achieving a BEP inflection around 2027 is seen as limited.

See why 1 investors see Ultragenyx Pharmaceutical as 40% undervalued.

Result: Fair Value of $26 (UNDERVALUED)

Still, Ultragenyx Pharmaceutical could surprise skeptics if pipeline assets hit key clinical milestones or if cost discipline tightens faster than this bitter recent share-price history implies.

Find out about the key risks to this Ultragenyx Pharmaceutical narrative.

Next Steps

There are mixed views on whether Ultragenyx Pharmaceutical is a turnaround opportunity or a value trap. Move quickly, review the numbers yourself, then weigh up the 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical might be front of mind today, but you give yourself a real edge when you compare it against other clear, data driven ideas on the same screen.

• Target potential under-the-radar bargains by scanning a 20 high quality undiscovered gems that couples strong fundamentals with quieter market attention.
• Strengthen the defensive side of your portfolio with a list of solid balance sheet and fundamentals (25 results) that can handle tougher conditions without stressing the books.
• Shift some capital toward resilience by filtering for 31 resilient stocks with low risk scores that combine quality metrics with lower historical risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com